Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.
The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.
UW's vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.
The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.
Co-founded by Stanford researchers, IgGenix is working on therapies that address severe allergies.
Based on research originally conducted at MIT, Tepha has been purchased by BD for an undisclosed sum.